Roth Capital adjusted the firm’s price target on Cellectar Biosciences (CLRB) to $18 from $3 and keeps a Buy rating on the shares post the Q2 report. The new price target largely reflects the company’s reverse split.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB: